Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

GERD does not seem to be a categorial disease

This month's American Journal of Gastroenterology reports that doctors observed progression and regression between grades in a large cohort of patients.

News image

fiogf49gjkf04

There is a controversy as to whether gastroesophageal reflux disease (GERD) exists as a spectrum of disease severity or as a categorial disease.

The categories are divided into 3 distinct groups, including nonerosive and erosive reflux disease, and Barrett's esophagus.

Dr Joachim Labenz and colleagues from Germany assessed progression or regression of GERD over 2 years in 3894 patients.

The patients were under routine clinical care in Germany, Austria, and Switzerland.

The investigative team recruited patients with predominant heartburn, with or without esophagitis.

The patients were classified according to endoscopic status at baseline.

The classification at baseline included nonerosive and erosive reflux disease-Los Angeles grade A/B or grade C/D, and Barrett's Esophagus.

Barrett's risk in erosive and nonerosive reflux disease was about 1%
American Journal of Gastroenterology

After an initial treatment with esomeprazole, the patients were followed, regardless of their response.

The investigators initiated medical therapy or endoscopy at the discretion of their primary care physician, in line with routine care.

At 2 years, the team performed endoscopy with biopsy according to the protocol.

After 2 years, 25% of patients who had nonerosive reflux disease at baseline progressed to Los-Angeles grade A/B, and less than 1% progressed to grade C/D.

The team noted that about 2% of patients who had Los Angeles grade A/B progressed to grade C/D, and 61% regressed to nonerosive reflux disease.

The investigators found that 42% with a Los Angeles C/D regressed to grade A/B, and 50% regressed to nonerosive reflux disease.

At 2 years, 22% of patients had been off medication for at least 3 months.

The team observed that those with erosive reflux disease and grade C/D were at greatest risk of developing Barrett's Esophagus, a risk of 6%.

For patients with erosive reflux disease and grade A/B, the risk was just over 1%.

The risk of developing Barrett's Esophagus in patients with nonerosive reflux disease, the risk was less than 1%.

Dr Labenz's team concludes, “GERD does not seem to be a categorial disease.”

“Progression and regression between grades was observed in this large cohort of patients under routine clinical care.”

Am J Gastroenterol 2006: 101(11): 2457
06 November 2006

Go to top of page Email this page Email this page to a colleague

 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us